Othman Al-Sawaf, MD

Othman Al-Sawaf, MD, is a hematologist and medical oncologist at the University Hospital Cologne, Cologne, Germany.

Articles by Othman Al-Sawaf, MD

Exploring the CLL14 Trial in Untreated CLL After 4 Years of Follow-up

August 11th 2021

Othman Al-Sawaf, MD, discusses the use of venetoclax plus obinutuzumab in patients with untreated chronic lymphocytic leukemia on the CLL14 study.

Examining Minimal Residual Disease Remissions in Patients With CLL

ByOthman Al-Sawaf, MD

March 11th 2021

Othman Al-Sawaf, MD, discusses an analysis of minimal residual disease in patients with chronic lymphocytic leukemia given venetoclax and obinutuzumab on the CLL14.

Othman Al-Sawaf, MD

Articles by Othman Al-Sawaf, MD

Exploring the CLL14 Trial in Untreated CLL After 4 Years of Follow-up

Examining Minimal Residual Disease Remissions in Patients With CLL

Latest Updated Articles

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL

Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC

JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update

LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors

Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma